Auro Laboratories Ltd. engages in the manufacture of active pharmaceutical ingredients, intermediates and generic formulations. The company is headquartered in Mumbai, Maharashtra. The firm operates through the Pharmaceuticals segment. The company offers APIs under categories, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids anti-inflammatory and others. Its products under intermediates include Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5, Trimethoxy Benzoic Acid and 5-Bromo Phthalide. The company also undertakes toll/custom manufacturing for APIs and Intermediates on contract basis. The firm has a presence in international markets with bulk of its production being exported to Southeast Asia, Middle East and several European Countries. Some of the countries it exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.